Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Intravascular ultrasound findings of the Fantom sirolimus-eluting bioresorbable scaffold at six- and nine-month follow-up: the FANTOM II study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Mechanical circulatory support for decompensated heart failure: the last remaining indication for intra-aortic balloon pump?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Transcatheter mitral valve repair: a step back from the edge

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The invisible army of women in interventional cardiology: EAPCI Women mission to make them visible

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Unreported exclusion and sampling bias in interpretation of randomized controlled trials in patients with STEMI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A nationwide investigation of CPR courses, books, and skill retention

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Laurens J C van Zandvoort
  • Dariusz Dudek
  • Joachim Weber-Albers
  • Alexandre Abizaid
  • Evald Høj Christiansen
  • David W M Muller
  • Janusz Kochman
  • Łukasz Kołtowski
  • Jens Flensted Lassen
  • Roman Wojdyla
  • Joanna J Wykrzykowska
  • Yoshinobu Onuma
  • Joost Daemen
Vis graf over relationer

AIMS: FANTOM II is a prospective multicentre trial assessing the safety and efficacy of the Fantom sirolimus-eluting bioresorbable coronary scaffold (BRS). The present substudy focuses on the six- and nine-month IVUS findings.

METHODS AND RESULTS: A total of 240 patients with de novo coronary artery lesions presenting with stable or unstable disease were included in two sequential cohorts (cohort A [n=117] and cohort B [n=123]) in which angiographic follow-up was performed at either six or nine months, respectively. Matched IVUS data were available for 35 paired cases in cohort A and 26 paired cases in cohort B. At six months, mean and minimum scaffold area (SA) decreased from 6.09±1.08 mm2 to 5.88±1.07 mm2, p=0.009, and 5.27±0.99 mm2 to 5.05±0.99 mm2, p=0.01, respectively. At nine months, no significant change in mean scaffold and minimum scaffold area was observed (6.46±1.11 mm2 to 6.38±0.96 mm2; p=0.35, and 5.45±1.00 mm2 to 5.36±0.86 mm2; p=0.32, respectively). Neointimal hyperplasia area was low at both six (0.11±0.12 mm2) and nine months (0.20±0.21 mm2), as was in-scaffold obstruction volume (1.94±2.25% at six months, and 3.40±4.11% at nine months).

CONCLUSIONS: The use of the Fantom BRS in stable coronary artery disease was associated with low rates of neointimal hyperplasia volume and in-scaffold volume obstruction at both six and nine months.

OriginalsprogEngelsk
TidsskriftEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Vol/bind14
Udgave nummer11
Sider (fra-til)e1215-e1223
ISSN1774-024X
DOI
StatusUdgivet - 7 dec. 2018

ID: 56521526